Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | PHASE3 | RECRUITING | 850 | — | — | Mar 16, 2026 | Dec 31, 2033 | Jun 3, 2026 | 255 | United States, Argentina +30 |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | PHASE3 | RECRUITING | 750 | — | — | Mar 12, 2026 | Oct 14, 2031 | Jun 3, 2026 | 273 | United States, Argentina +34 |
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm A: Pumitamig | EXPERIMENTAL | - |
| Arm B: Pembrolizumab | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Pumitamig | DRUG | Specified dose on specified days |
| Durvalumab | DRUG | Specified dose on specified days |
| Pembrolizumab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation...